ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gemcitabine

Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.

Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.

Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 6, 2000128 company-led studies, 9 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only681 open or runningphase 3since Nov 6, 2000Nov 6, 2000May 2027phase 2 · NCT05999994
Hoffmann-La Rocheits history only181 open or runningphase 4since Mar 19, 2008Apr 17, 2007Mar 22, 2027phase 1 · NCT06624085
Pfizerits history only50 open or runningphase 3since Jan 21, 2000Jan 21, 2000none ahead
GlaxoSmithKline40 open or runningphase 2since May 23, 2003May 23, 2003none ahead
Amgenits history only30 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Astellas Pharmaits history only20 open or runningphase 1since Apr 9, 2002Apr 9, 2002none ahead
NovoCureits history only20 open or runningphase 2since Oct 23, 2013Oct 23, 2013none ahead
Pierre Fabreits history only20 open or runningphase 2since Apr 16, 2012Apr 16, 2012none ahead
Sarah Cannon Research Instituteits history only20 open or runningphase 2since Apr 4, 2008Apr 4, 2008none ahead
Theriva Biologics SLits history only20 open or runningphase 1since Jan 21, 2014Jan 21, 2014none ahead

Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2003First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT00061308 · 75 enrolled · United States, Canada
  2. May 14, 2008Phase 1 study in Carcinoma, Non-Small-Cell LungNCT00678977 · 22 enrolled · Germany, United Kingdom
  3. Jan 22, 2011Phase 1 study in Pancreatic NeoplasmsNCT01324258 · 19 enrolled · Japan
  4. May 23, 2016Phase 2 study in Fanconi AnemiaNCT02797977 · 153 enrolled · Spain, United Kingdom

TargetBeta

“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
HydroxyurearuleNorginephase 415

Studies

All 4 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02797977Fanconi Anemia · Spain, United Kingdom2CompletedApr 8, 2020153
NCT01324258Pancreatic Neoplasms · Japan1CompletedJul 8, 201319
NCT00678977Carcinoma, Non-Small-Cell Lung · Germany, United Kingdom1CompletedMar 30, 201022
NCT00061308Ovarian Neoplasms · United States, Canada2CompletedSep 200475

How it is read

Names in the registry

  • “Gemcitabine”, 113 entries
  • “gemcitabine”, 52 entries
  • “gemcitabine hydrochloride”, 17 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “EndoTAG-1 and Gemcitabine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.